Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Of U.S. Seeks Indian Partnerships, Licenses For Biotech Drugs

This article was originally published in PharmAsia News

Executive Summary

U.S. biotech Gilead Science is ready to outsource manufacturing and research in India and seeks partnerships, an executive says. The firm also seeks to license more of its drugs in India, including its Viread HIV/AIDS drug at roughly $210 a year. Gilead already has ties to India's Piramal Healthcare for marketing the branded and generic versions of the drug at the same time. Several other Indian companies have been granted licenses to sell Viread at a price of their choosing. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC070790

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel